A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Interventional
Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Phase l: To establish the feasible dose levels/regimens based on End-of-cycle-1 dose limiting toxicity rate.
at every critical DLT, after 6 patients have completed cycle 1 or every 2 months
Yes
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
United States: Food and Drug Administration
CRAD001J2101
NCT00426556
July 2007
June 2013
Name | Location |
---|---|
Sammons Cancer Center | Dallas, Texas |
Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2) | Atlanta, Georgia 30322 |
Cancer Centers of the Carolinas CC of C -Eastside | Greenville, South Carolina 29605 |
Florida Cancer Care | Davie, Florida 33328 |
Wilshire Oncology Medical Group La Verne | *see Various Departments*, California |
North Shore University Health System | Skokie, Illinois 60077 |
Loma Linda University Dept.ofLomaLindaCancerCent(3) | Loma Linda, California |
Compassionate Cancer Care Medical Group Dept.ofCCCMG | Fountain Valley, California 92708 |
University of California at Los Angeles Dept.of UCLA Dept.ofMed. | Los Angeles, California 90095 |
Peninsula Regional Medical Center Deptof Oncology and Hematology | Salisbury, Maryland 21801 |
Washington University School Of Medicine-Siteman Cancer Ctr StudyCoordinator:CRAD001J2101 | St. Louis, Missouri 63110 |